摘要
目的：观察重组人脑利钠肽（rhBNP）治疗充血性心力衰竭的临床疗效。方法：选取我院和益阳市中心医院自2009年1月～12月收治的106例充血性心力衰竭患者随机分为观察组（重组人脑利钠肽治疗组）和对照组（常规治疗组）各53例，比较两组患者的治疗效果。结果：（1）两组治疗前后左室舒张末期内径（LVD）、左室后壁厚度（LVWP）、左室射血分数（LVEF）及心率变化均有明显差异（P〈0．05），具有统计学意义；且观察组与对照组进行组间比较也有明显差异（P〈0．05）。（2）对照组在治疗期间出现体位性低血压2例，恶心、呕吐2例，不良反应发生率为7．5％；观察组在治疗期间出现体位性低血压1例，不良反应发生率为1．9％。两组比较差异明显（P〈0．05），具有统计学意义。结论：重组人脑利钠肽（rhBNP）治疗充血性心力衰竭可以改善心脏功能、提高心脏射血分数、改善心衰症状，并且可以降低治疗过程中不良反应的发生率。
Objective： To observe the recombinant human brain natriuretic peptide （rhBNP） treatment of congestive heart failure patients. Methods： in our hospital from January 2009 to 12 months 106 patients admitted with congestive heart failure were, randomly divided into two groups （recombinant human brain natriuretic peptide in the treatment group） and control group （conventional treatment group） of the 53 cases, compared two groups of treatment. Results： （1） before and after treatment of left ventricular end diastolic diameter （LVD）, left ventricular posterior wall thickness （LVWP） and left ventricular ejection fraction （LVEF） changes were significantly different （P 〈0.05）, statistically significant ; and the observation group and control group comparison between groups also were significantly different （P 〈0. 05）. （2） control group during the treatment of orthostatie hypotension in 2 cases, nausea, vomiting, 2 cases of adverse reactions was 7.5%; observation group during the treatment of orthostatic hypotension, 1 case of adverse reactions was 1.9%. Significant difference between the two groups （P 〈0.05）, with statistical significance. Conclusion： Recombinant human brain natriuretic peptide （rhBNP） in patients with congestive heart failure can improve cardiac function, increased cardiac ejection fraction, improved heart failure symptoms and course of treatment can reduce the incidence of adverse reactions
关键词
重组人脑利钠肽
心力衰竭
充血性疗效
Recombinant human brain natriuretic peptide
Heart failure
Congestive
Effect
